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Abstract
Taiwan CDC investigated four cases of recurrent imported vivax malaria during 2003–2010. Molecular genotyping results and the lack
of inter-episodes travel history indicated that two of the patients, who acquired vivax malaria in Indonesia and the Solomon Islands,
respectively, suffered relapses after an interval of 3–4 months, despite completing standard-dose primaquine therapy (30 mg/day for
14 days) for the first episode. Treatment with a higher dose of primaquine (60 mg/day for 14 days) prevented further relapse in both
patients. This finding calls for further monitoring of the therapeutic efficacy of primaquine in treating Plasmodium vivax acquired in south-
east Asia and Oceania.
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Abstract
The results of Entamoeba histolytica infections range from asymptomatic colonization to variable disease outcomes. However, markers
that may predict infection outcomes are not known. Here, we investigated sequence types of a non-coding tRNA-linked locus R-R to
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identify surrogate markers that may show association with infection outcomes. Among 112 clinical samples—21 asymptomatic, 20 diar-
rhoea/dysentery and 71 liver abscesses—we identified 11 sequence types. Sequence type 5RR was mostly associated with asymptomatic
samples, and sequence type 10RR was predominantly associated with the symptomatic (diarrhoea/dysentery and liver abscess) samples.
This is the first report that identifies markers that may predict disease outcomes in E. histolytica infection.
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Abstract
The objective of this study was to validate the use of pftetQ and pfmdt genes as molecular markers of decreased in vitro susceptibility to
doxycycline in 113 Plasmodium falciparum isolates from Dakar, Senegal. The results show that copy numbers of pftetQ and pfmdt, esti-
mated by TaqMan real-time PCR, are not significantly associated with reduced susceptibility to doxycycline in vitro; however, the num-
ber of samples with a high doxycycline IC50 was likely to be too low to derive statistically significant results. Thus, no definitive
conclusions could be drawn. The markers should be further tested by analysing more isolates.
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